Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder

Psychiatry Investigation

Volumn 8, Issue 1, 2011, Pages 74-76

  Song, Ji Hye ^a   Yu, Bum Hee ^a   Lee, Dongsoo ^a   Yoon, Se Chang ^a   Jeon, Hong Jin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Discontinuation syndrome; Major depressive disorder; Suicide attempt; Venlafaxine

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMLODIPINE; CLONAZEPAM; GINKGO BILOBA EXTRACT; MIRTAZAPINE; PAROXETINE; TRAZODONE; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VENLAFAXINE;

ADULT; AGITATION; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; CASE REPORT; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG OVERDOSE; DRUG WITHDRAWAL; DYSPNEA; EPIGASTRIC PAIN; FOLLOW UP; GINKGO BILOBA; HUMAN; HYPERTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MALE; NAUSEA; PARESTHESIA; PHYSICIAN; SELF MEDICATION; SIDE EFFECT; SLEEP DISORDER; SUICIDE; TACHYCARDIA; THORAX DISEASE; THORAX PAIN; TINNITUS; TREMOR; VERTIGO;

EID: 79955518232     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2011.8.1.74     Document Type: Article

References (18)

1. Haddad P. Do antidepressants have any potential to cause addiction? J Psychopharmacol 1999;13:300-307.
2. Bolton JM, Robinson J Sareen J. Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. J Affect Disord 2009;115:367-375.
3. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-747.
4. Sadock BJ, Sadock VA. Synopsis of Psychiatry, 10th Edition. Philadelphia: Lippincott Williams & Wilkins; 2007.
5. Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006;67 Suppl 4:22-26.
6. Wyeth. Venlafaxine hydrochloride. Product's label. Philadelphia, 2006.
7. Cornford CS, Hill A, Reilly J. How patients with depressive symptoms view their condition: a qualitative study. Fam Pract 2007;24:358-364.
8. Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007;68:1472-1479.
9. Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005;66:1312-1320.
10. Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms-telephone calls to a national medication helpline. J Affect Disord 2006;95:129-133.
11. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomized study. J Psychopharmacol 2008;22:330-332.
12. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13:27-33.
13. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-579.
14. Long C, Crifasi J, Maginn D, Graham M, Teas S. Comparison of analytical methods in the determination of two venlafaxine fatalities. J Anal Toxicol 1997;21:166-169.
15. Berge KH, Seppala MD, Schipper AM. Chemical dependency and the physician. Mayo Clin Proc 2009;84:625-631.
16. Hughes PH, Brandenburg N, Baldwin DC Jr, Storr CL, Williams KM, Anthony JC, et al. Prevalence of substance use among US physicians. JAMA 1992;267:2333-2339.
17. McLellan AT, Skipper GS, Campbell M, DuPont RL. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ 2008;337:a2038.
18. Sattar SP, Grant KM, Bhatia SC. A case of venlafaxine abuse. N Engl J Med 2003;348:764-765.